Literature DB >> 9743287

Overexpression of the stathmin gene in a subset of human breast cancer.

I Bièche1, S Lachkar, V Becette, C Cifuentes-Diaz, A Sobel, R Lidereau, P A Curmi.   

Abstract

Stathmin is a highly conserved cytosolic phosphoprotein that destabilizes microtubules. Stathmin, which has been proposed as a relay protein integrating diverse cell signalling pathways, acts in vitro as a tubulin-sequestering protein, and its activity is dramatically reduced by phosphorylation. Interestingly, stathmin expression and phosphorylation are regulated during the control of cell growth and differentiation, and there is much evidence suggesting that in vivo stathmin plays a role in the control of microtubule dynamics during mitosis. Stathmin may thus be considered as one of the key regulators of cell division. We examined 50 human primary breast tumours for stathmin mRNA and protein expression and screened for abnormalities in the chromosome region harbouring the stathmin gene. Overexpression of stathmin was found in 15 tumours (30%). At the present stage, no clear correlation emerged between stathmin expression and several prognosis markers. Interestingly, perfect matching was observed between stathmin mRNA overexpression, protein overexpression and strong staining for stathmin on paraffin-embedded tumour sections when specimens were available. Furthermore, a tentative link between loss of heterozygosity (LOH) in the 1p32-1pter region and stathmin overexpression was observed. Our results suggest that stathmin might play a role in breast carcinogenesis and that stathmin-overexpressing tumours may represent a new subtype of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743287      PMCID: PMC2062973          DOI: 10.1038/bjc.1998.565

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Cell cycle progression is associated with distinct patterns of phosphorylation of Op18.

Authors:  J R Strahler; B J Lamb; D R Ungar; D A Fox; S M Hanash
Journal:  Biochem Biophys Res Commun       Date:  1992-05-29       Impact factor: 3.575

Review 2.  Stathmin: a relay phosphoprotein for multiple signal transduction?

Authors:  A Sobel
Journal:  Trends Biochem Sci       Date:  1991-08       Impact factor: 13.807

3.  Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells.

Authors:  S Jeha; X N Luo; M Beran; H Kantarjian; G F Atweh
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

4.  Stathmin phosphorylation is regulated in striatal neurons by vasoactive intestinal peptide and monoamines via multiple intracellular pathways.

Authors:  H Chneiweiss; J Cordier; A Sobel
Journal:  J Neurochem       Date:  1992-01       Impact factor: 5.372

5.  Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase.

Authors:  X N Luo; B Mookerjee; A Ferrari; S Mistry; G F Atweh
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

6.  High expression of stathmin in multipotential teratocarcinoma and normal embryonic cells versus their early differentiated derivatives.

Authors:  V Doye; O Kellermann; M H Buc-Caron; A Sobel
Journal:  Differentiation       Date:  1992-06       Impact factor: 3.880

7.  The phosphorylation of stathmin by MAP kinase.

Authors:  I A Leighton; P Curmi; D G Campbell; P Cohen; A Sobel
Journal:  Mol Cell Biochem       Date:  1993-11       Impact factor: 3.396

8.  A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer.

Authors:  I Bièche; M H Champème; R Lidereau
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

9.  The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control.

Authors:  U Marklund; O Osterman; H Melander; A Bergh; M Gullberg
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  27 in total

1.  Tumoral environment triggers transcript anomalies in established tumors: induction of altered gene expression and of aberrant, truncated and B2 repeat-containing gene transcripts.

Authors:  P Rottiers; M Desmedt; H Dooms; R Contreras; J Grooten
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.

Authors:  Bruce K Carney; Victoria Caruso Silva; Lynne Cassimeris
Journal:  Cytoskeleton (Hoboken)       Date:  2012-03-29

3.  Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.

Authors:  C Bai; B Connolly; M L Metzker; C A Hilliard; X Liu; V Sandig; A Soderman; S M Galloway; Q Liu; C P Austin; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

5.  Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray.

Authors:  Zhaoyang Zeng; Yanhong Zhou; Wei Xiong; Xiaomin Luo; Wenling Zhang; Xiaoling Li; Songqing Fan; Li Cao; Ke Tang; Minghua Wu; Guiyuan Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-21       Impact factor: 4.553

6.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

7.  Anti-centrosome antibodies in breast cancer are the expression of autoimmunity.

Authors:  Marie-Claire Maroun; Ofelia Olivero; Leonard Lipovich; Azadeh Stark; Larry Tait; Sudeshna Bandyopadhyay; Matthew Burke; Richard Zarbo; Dhananjay Chitale; S David Nathanson; Mike Long; Carol Peebles; Félix Fernández Madrid
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 8.  The individualization of cancer therapy: the unexpected role of p53.

Authors:  William N Hait; Jin-Ming Yang
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

9.  Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients.

Authors:  Wang Xi; Wang Rui; Lin Fang; Dong Ke; Gao Ping; Zhang Hui-Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

Review 10.  c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.

Authors:  Nancy D Ebelt; Michael A Cantrell; Carla L Van Den Berg
Journal:  Genes Cancer       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.